Should the Lambda (λ) Remain Silent?
详细信息 查看全文
- 作者：Hossein Haji Ali Afzali ; Jonathan Karnon ; Mark Sculpher
- 刊名：PharmacoEconomics
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：34
- 期：4
- 页码：323-329
- 全文大小：426 KB
- 参考文献：1.Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med. 2006;62:2091–100.CrossRef PubMed
2.Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy. 2007;12:56–8.CrossRef PubMed
3.Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
4.Higgins A, Barnett J, Meads C, et al. Does convenience matter in health care delivery? A systematic review of convenience-based aspects of process utility. Value Health. 2014;17:877–87.CrossRef PubMed
5.Gray AM, Clarke P, Wolstenholme J, Wordsworth S. Applied methods of cost-effectiveness analysis in health care. New York: Oxford University Press; 2011.
6.Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization: tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473–81.
7.Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Mak. 2000;20:332–42.CrossRef
8.McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold—what it is and what that means. Pharmacoeconomics. 2008;26:733–44.CrossRef PubMed
9.Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ. 2003;12:1049–60.CrossRef PubMed
10.Bobinac A, Van Exel NJ, Rutten FF, et al. Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health. 2010;13:1046–55.CrossRef PubMed
11.Cleemput I, Neyt M, Thiry N, et al. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess. 2011;27:71–6.CrossRef
12.Gyrd-Hansen D. Willingness to pay for a QALY—theoretical and methodological issues. Pharmacoeconomics. 2005;23:423–32.CrossRef PubMed
13.Pekarsky B. The new drug reimbursement game: a regulator’s guide to playing and winning. Cham, Switzerland: Springer International Publishing; 2014.
14.Paulden M, O’Mahony JF, Culyer AJ, et al. Some inconsistencies in NICE’s consideration of social values. Pharmacoeconomics. 2014;32:1043–53.CrossRef PubMed
15.Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1–504.CrossRef PubMed
16.Schaffer SK, Sussex J, Devlin N, et al. Local health care expenditure plans and their opportunity costs. Health Policy. 2015;119:1237–44.CrossRef
17.Committee Pharmaceutical Benefits Advisory. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: The Australian Government; 2013.
18.Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994–2004. Med Decis Making. 2008;28:713–22.CrossRef PubMed
19.Australian Government Department of Health. Ruxolitinib, tablets, 5 mg, 15 mg and 20 mg, Jakavi®. July 2013: Public summary document. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-07/ruxolitinib . Accessed 6 Jan 2015.
20.Australian Government Department of Health. Multicomponent meningococcal group B vaccine, 0.5 mL, injection, prefilled syringe, Bexsero®. November 2013: Public summary document. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-11/meningococcal-vaccine . Accessed 6 Jan 2015.
21.Australian Government Department of Health. Brentuximab vedotin, injection, 50 mg, Adcetris®. July 2014: Public summary document. http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-07/brentuximab-psd-07-2014.pdf . Accessed 2 Feb 2015.
22.Taylor RS, Drummond MF, Salkeld G, et al. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ. 2004;329:972–5.CrossRef PubMed PubMedCentral
23.George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making. Evidence from pharmaceutical reimbursement in Australia (1991–1996). Pharmacoeconomics. 2001;19:1103–9.CrossRef PubMed
24.Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518–28.CrossRef PubMed
25.Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J Health Serv Res Policy. 2006;11:46–51.CrossRef PubMed
26.Cleemput I, Neyt M, Thiry N, et al. Threshold values for cost-effectiveness in health care. Brussels: Belgian Health Care Knowledge Centre; 2008.
27.Deloitte Access Economics (Commissined by Medicines Australia). Access to cancer medicines in Australia. 2013. http://medicinesaustralia.com.au/files/2013/07/Access-to-oncology-medicines-1707-FINALV3.pdf . Accessed 7 Jan 2015.
28.Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336:251–4.CrossRef PubMed PubMedCentral
29.Griffin SC, Claxton KP, Palmer SJ, et al. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ. 2011;20:212–24.CrossRef PubMed
30.Claxton K. Oft, Vbp: Qed? Health Econ. 2007;16:545–58.CrossRef PubMed
31.Doyal L. The rationing debate: rationing within the NHS should be explicit—the case for. Brit Med J. 1997;314:1114–8.CrossRef PubMed PubMedCentral
32.Pharmaceutical Management Agency. Making funding decisions. Wellington: Pharmaceutical Management Agency; 2015.
33.National Institute for Health and Care Excellence (NICE). Consultation paper: value-based assessment of health technologies. London: NICE; 2014.
34.Goetghebeur MM, Wagner M, Khoury H, et al. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Mak. 2012;32:376–88.CrossRef
35.Claxton K, Sculpher M, Palmer S, Culyer AJ. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients? Health Econ. 2015;24:1–7.CrossRef PubMed
36.Coast J. The rationing debate: rationing within the NHS should be explicit—the case against. Brit Med J. 1997;314:1118–22.CrossRef PubMed PubMedCentral
37.Raftery JP. NICE’s cost-effectiveness range: should it be lowered? Pharmacoeconomics. 2014;32:613–5.CrossRef PubMed
38.Sculpher M, Claxton K. Real economics needs to reflect real decisions response. Pharmacoeconomics. 2012;30:133–6.CrossRef PubMed
39.Australian Government Department of Health. Sofosbuvir, 400 mg tablet, Sovaldi®. July 2014. Public summary document. http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2014-07/sofosbuvir-psd-07-2014.pdf . Accessed 10 Sep 2015.
40.Australian Government Department of Health. Sofosbuvir, 400 mg tablet, Sovaldi®. March 2015. Public smmary document. http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2015-03/Files/sofosbuvir-psd-march-2015.pdf . Accessed 10 Sep 2015.
41.Culyer AJ. Equity—some theory and its policy implications. J Med Ethics. 2001;27:275–83.CrossRef PubMed PubMedCentral
42.National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. London: NICE; 2013.
43.National Institute for Health and Clinical Excellence. NICE response to the first report of session 2007–2008. London: Stationery Office; 2009.
44.Longworth L, Sculpher MJ, Bojke L, Tosh JC. Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence. Int J Technol Assess Health Care. 2011;27:180–7.CrossRef PubMed
45.Barnsley P, Towse A, Karlsberg Schaffer S, Sussex J. Critique of CHE Research Paper 81: methods for the estimation of the NICE cost-effectiveness threshold. 2013. https://www.ohe.org/publications/critique-cheresearch-paper-81-methods-estimation-nice-cost-effectiveness-threshold . Accessed 10 Jan 2015.
46.Claxton C, Sculpher M. Response to the OHE critique of CHE Research paper 81. 2014. http://www.york.ac.uk/media/che/documents/Response%20to%20the%20OHE%20critique%20of%20CHE%20Research%20paper%2081.pdf . Accessed 4 Mar 2015. - 作者单位：Hossein Haji Ali Afzali (1)
Jonathan Karnon (1)
Mark Sculpher (2)
1. School of Public Health, University of Adelaide, Adelaide, SA, 5005, Australia
2. Centre for Health Economics, University of York, Heslington, York, UK - 刊物主题：Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Health Administration;
- 出版者：Springer International Publishing
- ISSN：1179-2027
文摘